Search
Now showing items 1-4 of 4
MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
(BMC Cancer, 2010-09-01)
BACKGROUND: Glioblastoma multiforme (GBM) is refractory to conventional therapies.
To overcome the problem of heterogeneity, more brain tumor markers are required for
prognosis and targeted therapy. We have identified and ...
EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
(PLoS One, 2014)
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and
is uniformly lethal. T-cell-based immunotherapy offers a promising platform for treatment
given its potential to specifically target tumor ...
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.
(Nature, 2015-03-19)
After stimulation, dendritic cells (DCs) mature and migrate to draining lymph nodes
to induce immune responses. As such, autologous DCs generated ex vivo have been pulsed
with tumour antigens and injected back into patients ...
MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
(BMC Cancer, 2010-09-01)
BACKGROUND: Glioblastoma multiforme (GBM) is refractory to conventional therapies.
To overcome the problem of heterogeneity, more brain tumor markers are required for
prognosis and targeted therapy. We have identified and ...